A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease

Meng Wei1, Meirong Huang, Shubao Chen

  • 1Department of Pediatric Cardiology, Shanghai Children's Medical Center, Medical Institute, Shanghai Jiaotong University, 1678, Dongfang Road, Shanghai, 200127, China.

Pediatric Cardiology
|March 28, 2015
PubMed

Insights

Kawasaki disease patients unresponsive to intravenous immunoglobulin (IVIG) are more likely to develop coronary artery lesions (CAL). Early, sufficient IVIG dosing and monitoring risk factors like lymph node enlargement can prevent non-response and CAL.

Area of Science:

  • Pediatrics
  • Immunology
  • Cardiology

Background:

  • Kawasaki disease (KD) is a critical pediatric illness.
  • Intravenous immunoglobulin (IVIG) is a primary treatment for KD.
  • Coronary artery lesions (CAL) are a major complication of KD.

Purpose of the Study:

  • To identify risk factors for IVIG non-response in KD patients.
  • To examine the relationship between IVIG non-response and CAL development.
  • To inform early intervention strategies for KD management.

Main Methods:

  • Retrospective analysis of 1953 KD patients' clinical records (1998-2007).
  • Univariate and multivariate statistical analyses were employed.
  • Logistic regression identified independent risk factors for IVIG non-response.

Main Results:

  • 6.8% of patients were IVIG non-responders; 18.6% developed CAL.
  • IVIG non-responders had a significantly higher incidence of CAL (31.3% vs. 17.6%).
  • Sufficient IVIG doses reduced non-response rates (5.2% vs. 18.1%).
  • Independent risk factors for non-response included lymph node enlargement, CAL, high ESR (≥75 mm/h), and high PLT count (≥530 × 10(9)/L).

Conclusions:

  • IVIG non-response is linked to increased CAL risk in KD.
  • Early and sufficient IVIG dosing is crucial for preventing non-response and CAL.
  • Cervical lymph node enlargement, elevated ESR, and high PLT count predict non-response to sufficient IVIG doses.
  • Consider combination therapy (hormones/immunosuppressants) for high-risk patients to mitigate non-response and CAL.

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
518
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
414
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
394
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.2K